Tenaya Therapeutics Inc TNYA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.72
- Day Range
- $0.70–0.73
- 52-Week Range
- $0.53–2.35
- Bid/Ask
- $0.70 / $0.71
- Shares Outstanding
- 217.00M
- Market Cap
- $154.46M
- Volume/Avg
- 1M / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 574.92
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 70
Valuation
|
Metric
|
TNYA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.47 |
Price/Sales | 574.92 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TNYA
|
|---|---|
Quick Ratio | 5.45 |
Current Ratio | 5.75 |
Interest Coverage | — |
Quick Ratio
TNYA
Profitability
|
Metric
|
TNYA
|
|---|---|
Return on Assets (Normalized) | −54.74% |
Return on Equity (Normalized) | −67.25% |
Return on Invested Capital (Normalized) | −63.09% |
Return on Assets
TNYA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Zcyqvqgdl | Nlglbc | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nybdhyjhs | Vvtyn | $64B | |||
| argenx SE ADR
ARGX
| Fwqfgyxy | Rst | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Tzylsmpp | Xqhyngx | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Cdcxtxgpl | Fvdvfrw | $24B | |||
| BioNTech SE ADR
BNTX
| Cbxccxd | Ztpdy | $23B | |||
| Incyte Corp
INCY
| Svzgpwvds | Ghcp | $22B | |||
| Moderna Inc
MRNA
| Fwmywmhtn | Qhmg | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Rlvbsvdc | Bbvz | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Nzddyjvm | Bmv | $13B |
United States